Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDE5 inhibitor study for endothelial function improvement in cardiovascular patients
ChiCTR1900022659Phase 4Not yet recruiting
- Sponsor
- Xiangya Hospital, Central South University
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sildenafil and tadalafil in coronary arteriosclerosis and erectile dysfunction (ED) (5 arms), sponsored by Xiangya Hospital, Central South University. Primary endpoints: IIEF-5, Endothelin-1 and 4 more. Planned start May 2019; status: not yet recruiting.
02
Drugs
sildenafiltadalafil
03
Conditions
coronary arteriosclerosiserectile dysfunction (ED)
Beyond the preview
Go deeper on ChiCTR1900022659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022659.